Skip to main content

Advertisement

SpringerLink
Log in

Causes of DMARD withdrawal following ADR within 6 months of initiation among Indian rheumatoid arthritis patients

  • Original Article
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

The present study was conducted in Indian rheumatoid arthritis (RA) patients prescribed disease-modifying anti-rheumatic drugs (DMARDs) to determine the incidence and type of adverse drug reactions (ADRs) leading to their withdrawal in the initial 6 months of therapy. This was considered important as pharmacogenetic variations in the pattern of RA in different populations and genetic differences in efficacy and safety to drugs demand separate studies to be conducted in different populations. Hospital records were used to identify 1,000 consecutive patients with RA fulfilling the American College of Rheumatology criteria and having at least 6-month follow-up. Age, gender, duration of arthritis, drug usage and ADR-related drug withdrawal were recorded from the charts. Most of the patients were put on single DMARD. Combined use of DMARD was less frequent and non-use of DMARD was common; however, disease control was good. The commonest DMARD used in our hospital was hydroxychloroquine 444 (44%) and the commonest combination used was methotrexate with hydroxychloroquine by 55 (6%). Sulphasalazine use showed preference to young and males. Supportive drugs used were NSAIDs by 883 (88%), corticosteroids by 646 (65%), paracetamol by 594 (59%) and amitriptyline by 88 (9%). Incidence of ADR-related DMARD withdrawal was maximum with leflunomide 2/15 (13.33%) followed by methotrexate 9/116 (7.76%), sulphasalazine 6/185 (3.24%), chloroquine 3/131 (2.29%) and hydroxychloroquine 8/444 (1.8%). Severity and symptomatology of disease, genetic pattern of patients, financial status, previous experience of the clinicians and patients, availability of drugs, patient expectations and compliance were the main factors that lead to a difference in pattern of therapy in our patients compared to other population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Malaviya AN, Kapoor SK, Singh RR et al (1993) Prevalence of rheumatoid arthritis in the adult Indian population. Rheumatol Int 13:131–134

    Article  PubMed  CAS  Google Scholar 

  2. Bedi GS, Gupta N, Handa R et al (2005) Quality of life in Indian patients with rheumatoid arthritis. Qual Life Res 14:1953–1958

    Article  PubMed  Google Scholar 

  3. Aggarwal A, Chandran S, Misra R (2006) Physical, psychosocial and economic impact of rheumatoid arthritis: a pilot study of patients seen at a tertiary care referral centre. Natl Med J India 19:187–191

    PubMed  Google Scholar 

  4. Gabriel SE, Crowson CS, Kremers HM et al (2003) Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum 48:54–58

    Article  PubMed  Google Scholar 

  5. Chakravarty K, McDonald H, Pullar T et al (2008) BSR & BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists. Rheumatology (Oxford) 47:924–925

    Google Scholar 

  6. Nell VPK, Machold KP, Eberl G et al (2004) Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology 43:906–914

    Article  PubMed  CAS  Google Scholar 

  7. Luqmani R, Hennell S, Estrach C et al (2006) British society for rheumatology and british health professionals in rheumatology guideline for the management of rheumatoid arthritis (the first two years). Rheumatology (Oxford) 45:1167–1169

    Google Scholar 

  8. Choy EHS, Smith C, Dore CJ et al (2005) A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal. Rheumatology 44:1414–1421

    Article  PubMed  CAS  Google Scholar 

  9. Handa R (2004) Management of rheumatoid arthritis. Natl Med J India 17:143–151

    PubMed  CAS  Google Scholar 

  10. American College of Rheumatology Ad hoc Committee on Clinical Guidelines (1996) Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 39:713–722

    Article  Google Scholar 

  11. American College of Rheumatology Ad hoc Committee on Clinical Guidelines (1996) Guidelines for monitoring drug therapy in rheumatoid arthritis. Arthritis Rheum 39:723–731

    Article  Google Scholar 

  12. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines (2002) Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 46:328–346

    Article  Google Scholar 

  13. Joshi VR (2002) Indian guidelines for the management of rheumatoid arthritis. J Assoc Physicians India 50:1207–1218

    Google Scholar 

  14. Van der Heijden JW, Dijkmans BA, Scheper RJ et al (2007) Drug insight: resistance to methotrexate and other disease-modifying antirheumatic drugs—from bench to bedside. Nat Clin Pract Rheumatol 3:26–34

    Article  PubMed  Google Scholar 

  15. Bingham S, Emery P (2000) Resistant rheumatoid arthritis clinics—a necessary development? Rheumatology (Oxford) 39:2–5

    Article  CAS  Google Scholar 

  16. Griffiths B, Situnayake RD, Clark B et al (2000) Racial origin and its effect on disease expression and HLA-DRB1 types in patients with rheumatoid arthritis: a matched cross-sectional study. Rheumatology (Oxford) 39:857–864

    Article  CAS  Google Scholar 

  17. Bruce N, Cronstein MD (2006) Pharmacogenetics in the rheumatic diseases. Bull NYU Hosp Jt Dis 64:16–19

    Google Scholar 

  18. Taniguchi A, Urano W, Tanaka E et al (2007) Pharmacogenomics of antirheumatic drugs and personalized medicine for rheumatoid arthritis. Nippon Rinsho 65:371–379

    PubMed  Google Scholar 

  19. Ranganathan P (2005) Pharmacogenetics of therapies in rheumatoid arthritis. Drugs Today (Barc) 41:799–814

    Article  CAS  Google Scholar 

  20. Tanaka E, Taniguchi A, Urano W et al (2004) Pharmacogenetics of disease-modifying anti-rheumatic drugs. Best Pract Res Clin Rheumatol 18:233–247

    Article  PubMed  CAS  Google Scholar 

  21. Taniguchi A, Urano W, Tanaka E et al (2002) Pharmacogenetics of disease modifying anti-rheumatic drugs. Nippon Rinsho 60:2339–2344

    PubMed  Google Scholar 

  22. Maetzel A, Wong A, Strand V et al (2000) Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs. Rheumatology (Oxford) 39:975–981

    Article  CAS  Google Scholar 

  23. Arnett FC, Edworthy SM, Bloch DA et al (1988) The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324

    Article  PubMed  CAS  Google Scholar 

  24. Maddison P, Kiely P, Kirkham B et al (2005) Leflunomide in rheumatoid arthritis: recommendations through a process of consensus. Rheumatology 44:280–286

    Article  PubMed  CAS  Google Scholar 

  25. Pavelka K, Forejtová Š, Pavelková A et al (2002) Analysis of the reasons for DMARD therapy discontinuation in patients with rheumatoid arthritis in the Czech and Slovak Republics. Clin Rheumatol 21:220–226

    Article  PubMed  CAS  Google Scholar 

  26. Nagashima M, Matsuoka T, Saitoh K et al (2006) Treatment continuation rate in relation to efficacy and toxicity in long-term therapy with low-dose methotrexate, sulfasalazine, and bucillamine in 1,358 Japanese patients with rheumatoid arthritis. Clin Exp Rheumatol 24:260–267

    PubMed  CAS  Google Scholar 

  27. Hoekstra M, van Ede AE, Haagsma CJ et al (2003) Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis. Ann Rheum Dis 62:423–426

    Article  PubMed  CAS  Google Scholar 

  28. van Ede E, Laan RFJM, Blom HJ et al (2002) Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis. Rheumatology 41:658–665

    Article  PubMed  Google Scholar 

  29. van Ede AE, Laan RF, Rood MJ et al (2001) Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: A forty-eight-week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 44:1515–1524

    Article  PubMed  CAS  Google Scholar 

  30. Joyce DA, Will RK, Hoffman DM et al (1991) Exacerbation of rheumatoid arthritis in patients treated with methotrexate after administration of folinic acid. Ann Rheum Dis 50:913–914

    Article  PubMed  CAS  Google Scholar 

  31. Pawlik A, Czerny B, Dabrowska-Zamojcin E et al (2005) The influence of IL-6 polymorphism on efficacy of treatment of rheumatoid arthritis patients with methotrexate and prednisone. Pol Arch Med Wewn 114:843–847

    PubMed  Google Scholar 

  32. Wessels JA, Kooloos WM, De Jonge R et al (2006) Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 54:2830–2839

    Article  PubMed  CAS  Google Scholar 

  33. Dervieux T, Furst D, Lein DO et al (2005) Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study. Ann Rheum Dis 64:1180–1185

    Article  PubMed  CAS  Google Scholar 

  34. Van Ede AE, Laan RF, Blom HJ et al (2001) The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients. Arthritis Rheum 44:2525–2530

    Article  PubMed  Google Scholar 

  35. Hughes LB, Beasley TM, Patel H et al (2006) Racial or ethnic differences in allele frequencies of single-nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence on response to methotrexate in rheumatoid arthritis. Ann Rheum Dis 65:1213–1218

    Article  PubMed  CAS  Google Scholar 

  36. Weisman MH, Furst DE, Park GS et al (2006) Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritis. Arthritis Rheum 54:607–612

    Article  PubMed  CAS  Google Scholar 

  37. Krajinovic M, Moghrabi A (2004) Pharmacogenetics of methotrexate. Pharmacogenomics 5:819–834

    Article  PubMed  CAS  Google Scholar 

  38. Ranganathan P, Eisen S, Yokoyama WM et al (2003) Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis? Ann Rheum Dis 62:4–9

    Article  PubMed  CAS  Google Scholar 

  39. Kremer JM (2006) Methotrexate pharmacogenomics. Ann Rheum Dis 65:1213–1218

    Article  Google Scholar 

  40. Suarez-Almazor ME, Belseck E, Shea BJ et al (2000) Sulfasalazine for treating rheumatoid arthritis (review). Cochrane Database Syst Rev 2:CD000958

    PubMed  Google Scholar 

  41. Wadelius M, Stjernberg E, Wiholm BE et al (2000) Polymorphisms of NAT2 in relation to sulphasalazine-induced agranulocytosis. Pharmacogenetics 10:35–41

    Article  PubMed  CAS  Google Scholar 

  42. Tanaka E, Taniguchi A, Urano W et al (2002) Adverse effects of sulfasalazine in patients with rheumatoid arthritis are associated with diplotype configuration at the N-acetyltransferase 2 gene. J Rheumatol 29:2492–2499

    PubMed  CAS  Google Scholar 

  43. Kitas GD, Farr M, Waterhouse L et al (1992) Influence of acetylator status on sulphasalazine efficacy and toxicity in patients with rheumatoid arthritis. Scand J Rheumatol 21:220–225

    Article  PubMed  CAS  Google Scholar 

  44. Bax DE, Greaves MS, Amos RS (1986) Sulphasalazine for rheumatoid arthritis: relationship between dose, acetylator phenotype and response to treatment. Br J Rheumatol 25:282–284

    Article  PubMed  CAS  Google Scholar 

  45. Pullar T, Hunter JA, Capell HA (1985) Effect of acetylator phenotype on efficacy and toxicity of sulphasalazine in rheumatoid arthritis. Ann Rheum Dis 44:831–837

    Article  PubMed  CAS  Google Scholar 

  46. Kumagai S, Komada F, Kita T et al (2004) N-acetyltransferase 2 genotype-related efficacy of sulfasalazine in patients with rheumatoid arthritis. Pharm Res 21:324–329

    Article  PubMed  CAS  Google Scholar 

  47. Teshima D, Hino B, Makino K et al (2003) Sulphasalazine-induced leucopenia in a patient with renal dysfunction. J Clin Pharm Ther 28:239–242

    Article  PubMed  CAS  Google Scholar 

  48. van der Heijden J, de Jong MC, Dijkmans BAC et al (2004) Acquired resistance of human T cells to sulfasalazine: stability of the resistant phenotype and sensitivity to nonrelated DMARDs. Ann Rheum Dis 63:131–137

    Article  PubMed  Google Scholar 

  49. Mohanty D, Mukherjee MB, Colah RB (2004) Glucose-6-phosphate dehydrogenase deficiency in India. Indian J Pediatr 71:525–529

    Article  PubMed  Google Scholar 

  50. Mavrikakis M, Papazoglou S, Sfikakis PP et al (1996) Retinal toxicity in long term hydroxychloroquine treatment. Ann Rheum Dis 55:187–189

    Article  PubMed  CAS  Google Scholar 

  51. Mavrikakis I, Sfikakis PP, Mavrikakis E et al (2003) The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal. Ophthalmology 110:1321–1326

    Article  PubMed  Google Scholar 

  52. Osiri M, Shea B, Robinson V et al (2003) Leflunomide for treating rheumatoid arthritis. Cochrane Database Syst Rev 1:CD002047

    PubMed  Google Scholar 

  53. Laivoranta-Nyman S, Mottonen T, Hannonen P et al (2006) Association of tumour necrosis factor a, b and c microsatellite polymorphisms with clinical disease activity and induction of remission in early rheumatoid arthritis. Clin Exp Rheumatol 24:636–642

    PubMed  CAS  Google Scholar 

  54. O’Dell JR, Nepom BS, Haire C et al (1998) HLA-DRB1 typing in rheumatoid arthritis: predicting response to specific treatments. Ann Rheum Dis 57:209–213

    Article  PubMed  Google Scholar 

  55. Kuuliala K, Orpana A, Leirisalo-Repo M et al (2006) Polymorphism at position +896 of the toll-like receptor 4 gene interferes with rapid response to treatment in rheumatoid arthritis. Ann Rheum Dis 65:1241–1243

    Article  PubMed  CAS  Google Scholar 

  56. Gotzsche PC, Johansen HK (2004) Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis. Cochrane Database Syst Rev 3:CD000189

    PubMed  Google Scholar 

  57. Saag KG, Criswell LA, Sems KM, Nettleman MD, Kolluri S (1996) Low-dose corticosteroids in rheumatoid arthritis. A meta-analysis of their moderate-term effectiveness. Arthritis Rheum 39:1818–1825

    Article  PubMed  CAS  Google Scholar 

  58. Seideman P (1993) Additive effect of combined naproxen and paracetamol in rheumatoid arthritis. Br J Rheumatol 32:1077–1082

    Article  PubMed  CAS  Google Scholar 

  59. Seideman P (1993) Paracetamol in rheumatoid arthritis. Agents Actions Suppl 44:7–12

    PubMed  CAS  Google Scholar 

  60. Frank RG, Kashani JH, Parker JC et al (1988) Antidepressant analgesia in rheumatoid arthritis. J Rheumatol 15:1632–1638

    PubMed  CAS  Google Scholar 

  61. Saarto T, Wiffen PJ (2005) Antidepressants for neuropathic pain. Cochrane Database Syst Rev 3:CD005454

    PubMed  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Pharmacology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India

    Niti Mittal & Vinu Jose

  2. Department of Internal Medicine, Nehru Hospital, F Block, 4th Floor, Postgraduate Institute of Medical Education and Research (PGIMER), Sector 12, Chandigarh, 160012, India

    Aman Sharma

  3. Department of Internal Medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India

    Ajay Wanchu & Pradeep Bambery

  4. Department of Pharmacology, Adesh Institute of Medical Sciences & Research (AIMSR), Bathinda, Punjab, India

    Rakesh Mittal

Authors
  1. Niti Mittal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aman Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vinu Jose
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rakesh Mittal
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ajay Wanchu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Pradeep Bambery
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aman Sharma.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mittal, N., Sharma, A., Jose, V. et al. Causes of DMARD withdrawal following ADR within 6 months of initiation among Indian rheumatoid arthritis patients. Rheumatol Int 32, 743–748 (2012). https://doi.org/10.1007/s00296-010-1646-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-010-1646-4

Keywords

Search

Navigation